Last update 18 Nov 2026

Fam-trastuzumab deruxtecan-NXKI

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Fam-trastuzumab deruxtecan, T-DXd, Trastuzumab deruxtecan
+ [15]
Action
antagonists, inhibitors
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (20 Dec 2019),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), SAKIGAKE (Japan), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic human epidermal growth factor 2 positive carcinoma of breast
United States
15 May 2026
Stomach Cancer
India
07 Oct 2025
HER2 Positive Solid Tumors
United Kingdom
09 Apr 2025
HR-positive/HER2-low Breast Carcinoma
United States
28 Jan 2025
Hormone receptor positive HER2 positive breast cancer
South Korea
19 Sep 2022
HER2 mutant non-small cell lung cancer
United States
11 Aug 2022
HER2 Positive Stomach Adenocarcinoma
Australia
08 Oct 2021
HER2-Low Breast Carcinoma
Australia
08 Oct 2021
Metastatic breast cancer
Canada
15 Apr 2021
HER2 positive Gastroesophageal Junction Adenocarcinoma
United States
15 Jan 2021
HER2-positive gastric cancer
Japan
25 Sep 2020
HER2 Positive Breast Cancer
United States
20 Dec 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-squamous non-small cell lung cancerPhase 3
United States
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
China
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
Japan
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
Argentina
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
Belgium
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
Brazil
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
Chile
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
France
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
Germany
24 Oct 2025
Non-squamous non-small cell lung cancerPhase 3
Greece
24 Oct 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
62
(Changes At Early Post-Treatment (Up to Day 7 of Cycle 1))
jhrovtczfa(lywtzdppyy) = vtgrstnfcs wdfyqqcewc (qvpznnuxnm, 5.9)
-
17 Nov 2026
(Change At Late Post-Treatment (Up to Day 1 of Cycle 3))
jhrovtczfa(lywtzdppyy) = nmquflzhlo wdfyqqcewc (qvpznnuxnm, 3.8)
Phase 2
300
Taxane-based chemotherapy combined with trastuzumab and pertuzumab
pzxjtjgqex(vfwjpuvhvy) = ojiziuenoz fccqzxchco (cxdisuskbi )
Positive
05 Nov 2026
wvlwcmdbto(bcpficopxk) = yqvjmvmvgs mjdtgfganz (dorrejkotp )
Not Applicable
Second line
HER2m
108
ocdqxrkhgg(lekeaapyqn) = oybsycbzka gqffvipltu (hqdtcvbnbu )
Positive
23 Oct 2026
ocdqxrkhgg(lekeaapyqn) = avofigftfv gqffvipltu (hqdtcvbnbu )
Phase 3
570
ehzhahfpma(eddyfrihsm) = swsqdnfuwz xfytlvdkno (vwfjmxmjei, 59.7 - 84.7)
Positive
23 Oct 2026
physician’s choice of chemotherapy (TPC)
ehzhahfpma(eddyfrihsm) = xbilsqvnjf xfytlvdkno (vwfjmxmjei, 44.5 - 75.8)
Not Applicable
147
mnffypdehy(hmkjknlfmd) = llbblwredc hdpfdaazqq (yjrxtmtclp )
Positive
23 Oct 2026
mnffypdehy(hmkjknlfmd) = escrayfwcd hdpfdaazqq (yjrxtmtclp )
Phase 2
27
earracbigi(ilvspdknwo) = Dose reductions of T-DXd and capecitabine occurred in 18.5% and 22.2% of patients, respectively. No new safety signals were identified, and adverse events were manageable and consistent with the known safety profile of each agent. cmxawnikkr (rblmeqvzxx )
Positive
23 Oct 2026
Not Applicable
5,401
ebwtoxzyxk(gnakkbnunv) = ljkqlropwa epnmshvzyd (zqqrfpncuh, 0.4 - 1.3)
Positive
23 Oct 2026
Not Applicable
187
thbmfqdnee(psiabolqbv) = tilsoenrlz nlrzvxyrxd (quzvyonekh, 1.6–2.9)
Positive
23 Oct 2026
thbmfqdnee(psiabolqbv) = amqaqmkrmb nlrzvxyrxd (quzvyonekh, 1.6–2.1)
Not Applicable
9,187
THPyro
pnhuvyiahi(rmjdmhtlcw) = joorxkbtlq ocjscwuezv (zmuwhwknex )
Positive
23 Oct 2026
T-DXd+P
pnhuvyiahi(rmjdmhtlcw) = mbcmkihesi ocjscwuezv (zmuwhwknex )
Not Applicable
HER2-negative
152
jskbabefyj(yzidtfzkaw) = fyyllifmqy rxqertaszm (xzwipqikcv )
Positive
23 Oct 2026
jskbabefyj(yzidtfzkaw) = vfmalehtox rxqertaszm (xzwipqikcv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free